Proventil HFA and Ventolin Have Similar Safety Profiles During Regular Use

¹ From the National Jewish Medical and Research Center, Denver
² From the Department of Medicine, University of Maryland, Baltimore
³ From the UCSD Medical Center, San Diego
⁴ From the 3M Pharmaceuticals, St. Paul, Minn.

Objective: As a secondary objective to a long-term study evaluating the bronchodilator effectiveness of Proventil HFA (albuterol), to assess the safety of Proventil HFA, Ventolin, and hydrofluoroalkane 134a (HFA-134a) placebo over 12 weeks of regular dosing.

Design: Randomized, double-blind, double-dummy parallel group, placebo-controlled, multicenter trial of asthmatics requiring inhaled β-adrenergic bronchodilators for symptom control.

Interventions: Treatment with Proventil HFA, Ventolin, or HFA-134a placebo, qid, for 12 weeks.

Measurements: Adverse events were reviewed at biweekly clinic visits. Between clinic visits, patients recorded morning and evening peak expiratory flow (PEF), asthma symptom and nighttime asthma sleep disturbance scores, and use of rescue β-adrenergic bronchodilator on diary cards daily. Investigators provided a global assessment of asthma control at weeks 0, 4, 8, and 12. Vital signs were recorded over 6 h after dosing with study drug at weeks 0, 4, 8, and 12. Standard laboratory tests, CBC count, serum chemistries, and urinalysis were obtained at study start and end.

Results: Adverse event reporting rates were similar for the three treatment groups. The morning PEF tended to be lower for the Proventil HFA and Ventolin groups than the HFA-134a placebo group, but the evening PEF tended to be higher for the active treatment groups. Daytime asthma symptom scores tended to be lower (better) with active treatment than placebo, but nighttime asthma sleep disturbance scores were similar for all three treatment groups. Use of Ventolin Rotacaps as rescue medication was significantly greater for the HFA-134a placebo group than the Proventil HFA and Ventolin groups. Diary card data did not change within groups over time. Investigator global assessments of asthma scores clustered between fair and good for all three treatment groups throughout the study. Changes in heart rate and BP were small after dosing with study drug and tended to be similar for the active treatments and HFA-134a placebo groups. No clinically meaningful changes in results of standard laboratory tests were found in any treatment group during this study.

Conclusions: Proventil HFA had a similar safety profile as Ventolin during regular use. A dosage of 16 puffs per day of propellant HFA-134a was well tolerated by asthmatics. Regular use of either Proventil HFA or Ventolin did not cause asthma control to deteriorate.

Key Words: albuterol • asthma • HFA-134a propellant

Submitted on March 18, 1997
Accepted on July 28, 1000

This article has been cited by other articles:

				F. S F Ram, J. Wright, D. Brocklebank, and J. E S White Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta 2 agonists bronchodilators in asthma BMJ, October 20, 2001; 323(7318): 901 - 901. [Abstract] [Full Text]

				J. Taylor, A. Kotch, K. Rice, M. Ghafouri, C. L. Kurland, N. M. Fagan, and T. J. Witek Jr Ipratropium Bromide Hydrofluoroalkane Inhalation Aerosol Is Safe and Effective in Patients With COPD Chest, October 1, 2001; 120(4): 1253 - 1261. [Abstract] [Full Text] [PDF]

				G. Shapiro, E. Bronsky, A. Murray, F. Barnhart, A. VanderMeer, and C. Reisner Clinical Comparability of Ventolin Formulated With Hydrofluoroalkane or Conventional Chlorofluorocarbon Propellants in Children With Asthma Arch Pediatr Adolesc Med, December 1, 2000; 154(12): 1219 - 1225. [Abstract] [Full Text] [PDF]

				J. W. Ramsdell, N. M. Klinger, B. P. Ekholm, and G. L. Colice Safety of Long-term Treatment With HFA Albuterol Chest, April 1, 1999; 115(4): 945 - 951. [Abstract] [Full Text] [PDF]

				J G Ayres, C D Frost, W F Holmes, D R R Williams, and S M Ward Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines BMJ, October 3, 1998; 317(7163): 926 - 930. [Abstract] [Full Text]